Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Intco Medical Technology Co., Ltd. (300677.SZ)
Zibo, CN
Intco Medical Technology Co., Ltd. is a company dedicated to the development, manufacturing, and worldwide distribution of both single-use medical products and durable medical equipment, serving markets within China and internationally. Their extensive product portfolio includes a variety of personal protective equipment like gloves, face masks, and shields, as well as essential clinical supplies such as ECG electrodes, medical apparel (e.g., isolation gowns), and hand hygiene solutions in both gel and spray forms. The company also produces specialized surgical components, including grounding pads, electrosurgical pencils, ESU cables, tip cleaners, and TENS electrodes. Beyond disposables, Intco Medical supplies a range of robust medical devices, notably mobility aids such as wheelchairs and scooters, along with other general medical apparatus. Their offerings further extend to temperature therapy items, emergency treatment provisions, products for maternal and infant care, and various home healthcare solutions. Established in 2009 and headquartered in Zibo, China, the company underwent a formal corporate name update in January 2020, maintaining its designation as Intco Medical Technology Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.37% | -8.68% | -23.80% | -0.93% | +0.88% | +11.70% | +83.26% | +87.61% | -44.94% | +698.71% | +698.71% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+4.2% Q1'26: +15.8% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-30.5% Q1'26: -97.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+11.1% Q1'26: -3.1% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+16.1% ★ Q1'26: +4.9% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+5.9% Q1'26: +1.5% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.7% ★ Q1'26: +7.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×6.85× Q1'26: 30.97× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.75B
est: 1.41B (+24.0%)
|
1.89B
est: 1.69B (+12.2%)
|
2.08B
est: 2.09B (-0.1%)
|
13.84B
est: 13.82B (+0.1%)
|
16.24B
est: 16.43B (-1.2%)
|
6.61B
est: 6.86B (-3.6%)
|
6.92B
est: 6.99B (-0.9%)
|
9.52B
est: 9.03B (+5.4%)
|
9.93B
est: 9.97B (-0.5%)
|
13.83B
13.47B – 14.18B
+38.7% YoY
|
15.09B
13.82B – 15.74B
+9.1% YoY
|
16.97B
16.59B – 17.35B
+12.5% YoY
|
| EBITDA |
265.62M
est: 432.48M (-38.6%)
|
265.52M
est: 516.71M (-48.6%)
|
308.96M
est: 638.93M (-51.6%)
|
8.76B
est: 4.23B (+106.9%)
|
8.95B
est: 5.03B (+77.9%)
|
556.79M
est: 2.10B (-73.5%)
|
557.08M
est: 2.14B (-74.0%)
|
1.74B
est: 2.09B (-16.8%)
|
2.57B
est: 2.31B (+11.2%)
|
3.20B
3.12B – 3.28B
+38.7% YoY
|
3.49B
3.20B – 3.64B
+9.1% YoY
|
3.93B
3.84B – 4.02B
+12.5% YoY
|
| EBIT |
200.23M
est: 341.75M (-41.4%)
|
185.96M
est: 408.31M (-54.5%)
|
216.76M
est: 504.88M (-57.1%)
|
8.62B
est: 3.34B (+157.6%)
|
8.58B
est: 3.98B (+115.8%)
|
-70.28M
est: 1.66B (-104.2%)
|
-162.49M
est: 1.69B (-109.6%)
|
885.29M
est: 1.35B (-34.5%)
|
1.60B
est: 1.49B (+7.1%)
|
2.07B
2.02B – 2.12B
+38.7% YoY
|
2.26B
2.07B – 2.36B
+9.1% YoY
|
2.54B
2.48B – 2.60B
+12.5% YoY
|
| Net Income |
145.08M
est: 134.49M (+7.9%)
|
179.34M
est: 165.72M (+8.2%)
|
178.32M
est: 208.94M (-14.7%)
|
7.01B
est: 7.45B (-6.0%)
|
7.43B
est: 7.41B (+0.3%)
|
629.07M
est: 570.63M (+10.2%)
|
383.00M
est: 350.16M (+9.4%)
|
1.47B
est: 1.21B (+21.1%)
|
1.01B
est: 1.25B (-19.3%)
|
2.20B
2.10B – 2.29B
+75.4% YoY
|
2.75B
2.22B – 3.03B
+25.1% YoY
|
3.27B
3.20B – 3.34B
+19.0% YoY
|
| SGA |
165.44M
est: 107.73M (+53.6%)
|
194.27M
est: 128.72M (+50.9%)
|
216.92M
est: 159.16M (+36.3%)
|
563.68M
est: 1.05B (-46.5%)
|
921.73M
est: 1.25B (-26.5%)
|
612.38M
est: 523.64M (+16.9%)
|
738.31M
est: 532.95M (+38.5%)
|
806.58M
est: 677.48M (+19.1%)
|
340.34M
est: 747.95M (-54.5%)
|
1.04B
1.01B – 1.06B
+38.7% YoY
|
1.13B
1.04B – 1.18B
+9.1% YoY
|
1.27B
1.24B – 1.30B
+12.5% YoY
|
| EPS |
0.32
est: 0.21 (+54.3%)
|
0.34
est: 0.26 (+33.0%)
|
0.34
est: 0.32 (+5.5%)
|
12.21
est: 11.49 (+6.2%)
|
11.37
est: 11.43 (-0.5%)
|
0.99
est: 0.88 (+12.5%)
|
0.58
est: 0.54 (+7.4%)
|
2.26
est: 1.88 (+20.2%)
|
1.58
est: 1.97 (-19.9%)
|
3.41
3.26 – 3.56
+73.0% YoY
|
4.24
3.44 – 4.70
+24.3% YoY
|
5.08
4.98 – 5.18
+19.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck ChiNext ETF CNXT | 0.29% | 350.7K | 0.65% |
| 2 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.20% | 73.4K | 0.65% |
| 3 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.06% | 9.1K | 0.65% |
| 4 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.05% | 35.9K | 0.55% |
| 5 | State Street SPDR S&P China ETF GXC | 0.04% | 176.9K | 0.59% |
| 6 | Franklin FTSE China ETF FLCH | 0.02% | 44.8K | 0.19% |
| 7 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 207.5K | 0.19% |
| 8 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.01% | 34.2K | 0.49% |
| 9 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.00% | 25.5K | 0.40% |
| 10 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 407.4K | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Feng Jie | CFO & Secretary | — | female |
| Hai Sheng Yu | Deputy GM & Non-Independent Director | — | male |
| Qiong Chen | GM & Director | — | female |
| Ye Tang | Chairman of the Board of Supervisors | — | male |
| Yufa Jiao | Head of Accounting Department | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300677.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
